On Friday 11/08/2024 the closing price of the Merck Co. share was $102.98 on BTT.
Compared to the opening price on Friday 11/08/2024 on BTT of $101.40, this is a gain of 1.53%.
Merck Co.'s market capitalization is $224.45 B by 2.53 B shares outstanding.
Is Merck stock a Buy, Sell or Hold?
Merck stock has received a consensus rating of buy. The average rating score is A1 and is based on 45 buy ratings, 9 hold ratings, and 1 sell ratings.What was the 52-week low for Merck stock?
The low in the last 52 weeks of Merck stock was 98.60. According to the current price, Merck is 104.59% away from the 52-week low.What was the 52-week high for Merck stock?
The high in the last 52 weeks of Merck stock was 134.61. According to the current price, Merck is 76.61% away from the 52-week high.What are analysts forecasts for Merck stock?
The 55 analysts offering price forecasts for Merck have a median target of 129.95, with a high estimate of 155.00 and a low estimate of 99.00. The median estimate represents a 79.36 difference from the last price of 103.13.Merck Stock Snapshot
102.83
Bid
1.00
Bid Size
103.01
Ask
100.00
Ask Size
11/8/2024
Date
4:35 PM
Time
412,266.00
Volume
102.98
Prev. Close
101.40
Open
256.45 B
Market Cap in USD
2.53 B
Number of Shares
2.53 B
Total Number of Shares
101.04
Day Low
103.23
Day High
103.13
98.60
52 Week Low
134.61
52 Week High
103.13
2.96
Dividend in USD
2.72
Dividend Yield
760.78
P/E Ratio
99.90
Free Float in %
0.14
EPS in USD
14.84
Book Value per Share in USD
5.11
Cash Flow per Share in USD
Merck News More News
Historical Prices for Merck
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Merck Analyst Data
Total Analysts: 55
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 99.00
Median: 129.95
Highest: 155.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Merck Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/11/24 | Morgan Stanley | Maintained Hold | $134 | |||
| 06/18/24 | Cantor Fitzgerald | Maintained Buy | $155 | |||
| 06/04/24 | Cantor Fitzgerald | Maintained Buy | $155 | |||
| 04/18/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 04/08/24 | Berenberg | Maintained Buy | $143 | |||
| 04/05/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 04/01/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 03/27/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 03/27/24 | Wells Fargo & Co | Maintained Hold | $135 | |||
| 03/11/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 02/29/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 02/14/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 02/05/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 02/02/24 | UBS | Maintained Buy | $148 | |||
| 02/02/24 | Wells Fargo & Co | Maintained Hold | $130 | |||
| 02/02/24 | Barclays Capital | Maintained Buy | $145 | |||
| 01/23/24 | Barclays Capital | Maintained Buy | $135 | |||
| 01/09/24 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 11/29/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 11/20/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 11/15/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 11/09/23 | Deutsche Bank | Maintained Buy | $115 | |||
| 10/27/23 | Morgan Stanley | Maintained Hold | $118 | |||
| 10/27/23 | BMO Capital Markets | Upgraded to Buy | $132 | |||
| 10/23/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 10/11/23 | Morgan Stanley | Maintained Hold | $115 | |||
| 10/02/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 09/05/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 08/22/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 08/02/23 | Morgan Stanley | Maintained Hold | $116 | |||
| 07/14/23 | HSBC | Maintained Sell | $123 | |||
| 07/11/23 | Morgan Stanley | Maintained Hold | $109 | |||
| 05/30/23 | Cantor Fitzgerald | Maintained Buy | $135 | |||
| 05/01/23 | Atlantic Equities | Maintained Buy | $129 | |||
| 05/01/23 | Barclays Capital | Maintained Buy | $130 | |||
| 04/13/23 | Citigroup Corp. | Upgraded to Buy | $130 | |||
| 04/11/23 | Guggenheim | Maintained Buy | $124 | |||
| 04/10/23 | Mizuho | Maintained Buy | $130 | |||
| 03/17/23 | Mizuho | Maintained Buy | $130 | |||
| 03/13/23 | Wells Fargo & Co | Downgraded to Hold | $115 | |||
| 03/10/23 | Berenberg | Maintained Buy | $130 | |||
| 03/07/23 | Credit Suisse | Maintained Buy | $126 | |||
| 03/07/23 | Atlantic Equities | Maintained Buy | $127 | |||
| 03/06/23 | Jefferies & Company Inc. | Maintained Buy | $125 | |||
| 02/23/23 | J.P. Morgan | Maintained Buy | $125 | |||
| 02/22/23 | Wolfe Research | Upgraded to Buy | $127 | |||
| 02/13/23 | Credit Suisse | Maintained Buy | $125 | |||
| 02/03/23 | Wells Fargo & Co | Maintained Buy | $120 | |||
| 02/03/23 | Morgan Stanley | Maintained Hold | $99 | |||
| 02/03/23 | SVB Leerink | Maintained Buy | $122 |
Merck Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 64,065 | 67,216 | 71,054 | 73,997 | 74,231 |
| Dividend | 3.05 | 3.21 | 3.37 | 3.66 | 3.83 |
| Dividend Yield (in %) | 2.95 % | 3.11 % | 3.27 % | 3.54 % | 3.71 % |
| EPS | 7.76 | 9.41 | 10.36 | - | - |
| P/E Ratio | 13.28 | 10.96 | 9.95 | 9.17 | 9.30 |
| EBIT | 24,049 | 28,371 | 30,937 | 33,014 | 32,258 |
| EBITDA | 27,062 | 31,050 | 33,488 | - | - |
| Net Profit | - | - | - | - | - |
| Net Profit Adjusted | - | - | - | - | - |
| Pre-Tax Profit | 23,906 | 28,267 | 31,014 | - | - |
| Pre-Tax Profit Reported | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | 7.76 | 9.41 | 10.36 | - | - |
| EPS (GAAP) | 7.51 | 8.98 | 9.88 | - | - |
| Gross Income | 51,825 | 54,616 | 57,334 | 59,470 | 59,934 |
| Cash Flow from Investing | -4,820 | -4,757 | - | - | -4,780 |
| Cash Flow from Operations | 22,118 | 25,729 | 27,965 | - | 30,241 |
| Cash Flow from Financing | -7,469 | -9,516 | -9,403 | -9,520 | -9,697 |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | 20,953 | 24,887 | 26,807 | 28,210 | 27,546 |
| Free Cash Flow per Share | 7.88 | 8.82 | 9.78 | - | - |
| Book Value per Share | 18.42 | 23.27 | 28.87 | - | - |
| Net Debt | 21,728 | 7,516 | -5,408 | - | - |
| Research & Development Exp. | 16,296 | 15,124 | 15,472 | 15,874 | 15,896 |
| Capital Expenditure | 3,507 | 3,394 | 3,468 | 3,240 | 3,126 |
| Selling, General & Admin. Exp. | 10,846 | 11,244 | 11,453 | 11,733 | 11,735 |
| Shareholder’s Equity | 48,303 | 62,649 | 79,110 | - | - |
| Total Assets | 116,700 | 130,637 | 146,928 | - | 181,420 |
|
Previous Quarter ending 09/30/24 |
Current Quarter ending 12/31/24 |
Next Quarter ending 03/31/25 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | - | 3 | 16 | 20 |
| Average Estimate | - | - | 2.276 USD | 7.764 USD | 9.421 USD |
| Year Ago | - | - | 1.880 USD | 0.144 USD | - |
| Publish Date | - | - | 4/24/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 14 | 2 | 18 | 18 |
| Average Estimate | - | 15,548 USD | 16,280 USD | 64,065 USD | 67,216 USD |
| Year Ago | - | 14,213 USD | 15,809 USD | 59,871 USD | - |
| Publish Date | - | 2/4/2025 | 4/24/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 59,871.00 | 58,473.00 | 48,907.00 | 48,013.00 | 46,586.00 | 42,446.00 | 39,981.00 |
| Change of sales in % | 2.39 | 19.56 | 1.86 | 3.06 | 9.75 | 6.17 | 1.23 |
| Gross profit on sales | 43,894.00 | 41,267.00 | 35,441.00 | 35,421.00 | 32,725.00 | 29,381.00 | 27,402.00 |
| Gross profit on sales change in % | 6.37 | 16.44 | 0.06 | 8.24 | 11.38 | 7.22 | 4.86 |
| Operating income | 2,982.00 | 19,501.00 | 15,619.00 | 12,566.00 | 13,480.00 | 9,684.00 | 8,001.00 |
| Operating income change in % | -84.71 | 24.85 | 24.30 | -6.78 | 39.20 | 21.03 | -23.73 |
| Income before tax | 1,889.00 | 16,444.00 | 13,879.00 | 8,791.00 | 11,464.00 | 8,701.00 | 6,521.00 |
| Income before tax change in % | -88.51 | 18.48 | 57.88 | -23.32 | 31.75 | 33.43 | 39.97 |
| Income after tax | 365.00 | 14,519.00 | 12,345.00 | 7,067.00 | 9,843.00 | 6,220.00 | 2,394.00 |
| Income after tax change in % | -97.49 | 17.61 | 74.69 | -28.20 | 58.25 | 159.82 | -38.93 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 69,040.00 | 63,102.00 | 67,437.00 | 66,184.00 | 58,396.00 | 55,755.00 | 53,303.00 |
| Long-term liabilities per share | 17.12 | 15.31 | 17.24 | 15.36 | 14.25 | 12.94 | 12.86 |
| Equity | 37,635.00 | 46,058.00 | 38,257.00 | 25,404.00 | 26,001.00 | 26,882.00 | 34,569.00 |
| Equity change in % | -18.29 | 20.45 | 50.82 | -2.28 | -2.97 | -22.24 | -14.35 |
| Balance sheet total | 106,675.00 | 109,160.00 | 105,694.00 | 91,588.00 | 84,397.00 | 82,637.00 | 87,872.00 |
| Balance sheet total change in % | -2.28 | 3.28 | 15.40 | 8.52 | 2.13 | -5.96 | -7.87 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 23.51 | 23.00 | 19.27 | 18.90 | 18.06 | 15.84 | 14.55 |
| P/E ratio (year end quote, basic EPS) | 760.78 | 19.43 | 14.91 | 29.41 | 23.84 | 32.94 | 64.68 |
| P/E ratio (year end quote, diluted EPS) | 760.78 | 19.43 | 14.91 | 29.41 | 23.84 | 32.94 | 64.68 |
| P/E ratio (year end quote) | 760.78 | 19.43 | 14.91 | 29.41 | 23.84 | 32.94 | 64.68 |
| Dividend yield in % | 2.72 | 2.52 | 3.44 | 3.03 | 2.48 | 2.60 | 3.36 |
| Equity ratio in % | 35.28 | 42.19 | 36.20 | 27.74 | 30.81 | 32.53 | 39.34 |
| Debt ratio in % | 64.72 | 57.81 | 63.80 | 72.26 | 69.19 | 67.47 | 60.66 |
Merck Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Guindo Chirfi | 08/04/2024 | 17,412.00 | 40,369.59 | 115.20 | Sell | No |
| Guindo Chirfi | 08/04/2024 | 36,901.00 | 57,781.59 | 115.20 | Buy | No |
| Smart Dalton | 05/03/2024 | 302.00 | 4,428.29 | 127.51 | Sell | No |
| Klobuchar Michael A | 05/03/2024 | 437.00 | 23,621.20 | 127.51 | Sell | No |
| DeLuca Richard R. | 05/03/2024 | 13,360.00 | 150,359.56 | 127.51 | Sell | No |
| Klobuchar Michael A | 05/03/2024 | 887.00 | 24,058.20 | 127.51 | Buy | No |
| Smart Dalton | 05/03/2024 | 612.00 | 4,730.29 | 127.51 | Buy | No |
| DeLuca Richard R. | 05/03/2024 | 27,126.00 | 163,719.56 | 127.51 | Buy | No |
| Smart Dalton | 05/02/2024 | 255.00 | 3,178.29 | 128.26 | Sell | No |
| Smart Dalton | 05/02/2024 | 590.00 | 4,118.29 | 128.26 | Sell | No |
| Smart Dalton | 05/02/2024 | 1,530.00 | 4,708.29 | 128.26 | Buy | No |
| Smart Dalton | 05/02/2024 | 516.00 | 3,433.29 | 128.26 | Buy | No |
| Romanelli Joseph | 05/01/2024 | 1,115.00 | 20,716.33 | 128.80 | Sell | No |
| Romanelli Joseph | 05/01/2024 | 2,262.00 | 21,831.33 | 128.80 | Buy | No |
| Litchfield Caroline | 02/13/2024 | 38,291.00 | 50,908.19 | 125.50 | Sell | No |
| Litchfield Caroline | 02/13/2024 | 38,291.00 | 89,199.19 | 58.08 | Buy | No |
| MIZELL STEVEN | 02/01/2024 | 50,694.00 | 23,619.15 | 126.65 | Sell | No |
| MIZELL STEVEN | 02/01/2024 | 824.00 | 42,143.15 | 70.71 | Buy | No |
| MIZELL STEVEN | 02/01/2024 | 32,170.00 | 74,313.15 | 73.73 | Buy | No |
| Zachary Jennifer | 01/21/2024 | 23,298.00 | 59,139.76 | 119.43 | Buy | No |
| Klobuchar Michael A | 01/21/2024 | 3,896.00 | 23,098.14 | 119.43 | Buy | No |
| Davis Robert M | 01/21/2024 | 76,510.00 | 348,326.76 | 119.43 | Buy | No |
| Smart Dalton | 01/21/2024 | 2,661.00 | 2,667.25 | 119.43 | Buy | No |
| Litchfield Caroline | 01/21/2024 | 19,208.00 | 50,908.19 | 119.43 | Buy | No |
| Chattopadhyay Sanat | 01/21/2024 | 26,716.00 | 26,716.00 | 119.43 | Buy | No |
Merck Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Merck Co. | 2.96 | 2.72 | USD |
| 2022 | Merck Co. | 2.80 | 2.52 | USD |
| 2021 | Merck Co. | 2.64 | 3.44 | USD |
| 2020 | Merck Co. | 2.48 | 3.03 | USD |
| 2019 | Merck Co. | 2.26 | 2.48 | USD |
| 2018 | Merck Co. | 1.99 | 2.60 | USD |
| 2017 | Merck Co. | 1.89 | 3.36 | USD |
| 2016 | Merck Co. | 1.85 | 3.14 | USD |
| 2015 | Merck Co. | 1.81 | 3.43 | USD |
| 2014 | Merck Co. | 1.77 | 3.12 | USD |
| 2013 | Merck Co. | 1.73 | 3.46 | USD |
| 2012 | Merck Co. | 1.69 | 4.13 | USD |
| 2011 | Merck Co. | 1.56 | 4.14 | USD |
| 2010 | Merck Co. | 1.52 | 4.22 | USD |
| 2009 | Merck Co. | 1.52 | 4.16 | USD |
| 2008 | Merck Co. | 1.52 | 5.00 | USD |
| 2007 | Merck Co. | 1.52 | 2.62 | USD |
| 2006 | Merck Co. | 1.52 | 3.49 | USD |
| 2005 | Merck Co. | 1.52 | 4.78 | USD |
| 2004 | Merck Co. | 1.49 | 4.64 | USD |
| 2003 | Merck Co. | 1.45 | 3.14 | USD |
| 2002 | Merck Co. | 1.41 | 2.49 | USD |
| 2001 | Merck Co. | 1.37 | 2.33 | USD |
| 2000 | Merck Co. | 1.21 | 1.29 | USD |
| 1999 | Merck Co. | 1.12 | 1.67 | USD |
*Yield of the Respective Date
Merck Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | - | Q4 2024 Earnings Release | 02/04/2025 |
| Earnings Report | 2.276 USD | Q1 2025 Earnings Release | 04/24/2025 |
| Earnings Report | 2.425 USD | Q2 2025 Earnings Release | 07/29/2025 |
| Earnings Report | 2.565 USD | Q3 2025 Earnings Release | 10/30/2025 |
| Earnings Report | 2.181 USD | Q4 2025 Earnings Release | 01/29/2026 |
| Earnings Report | - | Q1 2026 Earnings Release | 04/23/2026 |
| Earnings Report | - | Q2 2026 Earnings Release | 08/04/2026 |
| Earnings Report | - | Q3 2026 Earnings Release | 11/03/2026 |
Merck Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 1.240 USD | Q3 2024 Earnings Release | 10/31/2024 |
Merck Profile
Merck & Co. , Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Moody’s Daily Credit Risk Score
Merck Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.90 |
| The Vanguard Group, Inc. | 9.66 |
| Vanguard Group, Inc. (Subfiler) | 9.19 |
| State Street Corp. | 4.64 |
| Vanguard Total Stock Market ETF | 3.17 |
| BlackRock Fund Advisors | 2.80 |
| Wellington Management Co. LLP (Wellington Breakout) | 2.71 |
| Vanguard 500 Index Fund | 2.62 |
| Geode Capital Management LLC | 2.25 |
| BlackRock Institutional Trust Co. NA | 2.23 |
| Fidelity Management & Research Co. LLC | 1.51 |
| Norges Bank (13F) | 1.33 |
| Fidelity 500 Index Fund | 1.23 |
| Blackrock Group Ltd. (Subfiler) | 0.97 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 0.83 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Merck Management
| Name | Job |
|---|---|
| James Matteucci | Associate Director-State Government Affairs |
| Robert M. Davis | Chairman, President & Chief Executive Officer |
| Caroline A. Litchfield | Chief Financial Officer & Executive Vice President |
| Betty D. Larson | Chief Human Resources Officer & Executive VP |
| Dave Williams | Chief Information & Digital Officer |
| Chirfi Guindo | Chief Marketing Officer-Human Health & SVP |
| Michael Klobuchar | Chief Strategy Officer & Executive Vice President |
| Sanat Chattopadhyay | EVP & President-Merck Manufacturing Division |
| Dean Y. Li | EVP & President-Merck Research Laboratories |
| Brooke Hinkson | Executive Director-Global Clinical Data Standards |
| Jennifer Zachary | Executive Vice President & General Counsel |
| Richard R. DeLuca | Executive Vice President & President-Animal Health |
| Christine E. Seidman | Independent Director |
| Douglas M. Baker | Independent Director |
| Inge G. Thulin | Independent Director |
| Kathy J. Warden | Independent Director |
| Mary Ellen Coe | Independent Director |
| Pamela J. Craig | Independent Director |
| Patricia Fiorello Russo | Independent Director |
| Paul B. Rothman | Independent Director |
| Risa J. Lavizzo-Mourey | Independent Director |
| Stephen L. Mayo | Independent Director |
| Thomas Henry Glocer | Lead Independent Director |
| Sylvia A. Ayler | Legal Director |
| Carol Bowden | Med Aff. Dir, Cardiovascular Metabolism, NorCal |
| Allan Gabor | President-Asian-Pacific-BioPharma Business |
| Joseph Romanelli | President-Human Health International |
| Jannie Oosthuizen | President-Merck Human Health |
| Andre Musto | SVP & Head-Gbl Cardiometabolic & Endoc Franchise |
| Kelly E. W. Grez | Secretary |
| Fiona Hamilton Marshall | Senior VP & Global Head-Discovery Sciences |
| Eric H. Rubin | Senior VP-Global Clinical Oncology |
| Dalton E. Smart | Senior Vice President-Finance & Global Controller |
| Denise Williams | Vice President |
| Johanna Herrmann | Vice President-Global Communications |
| Peter Dannenbaum | Vice President-Investor Relations |